Market Price

175.47 

0.20 0.1%

as of Jan 15 '21

52 Week Range:

89.62 176.19


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Varian Medical Systems, Inc. designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide. It operates through Oncology Systems and Proton Solutions segments. The Oncology Systems segment offers hardware and software products for treating cancer with radiotherapy, fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, artificial intelligence based adaptive radiotherapy, and brachytherapy, as well as quality assurance equipment. Its products include linear accelerators, brachytherapy afterloaders, treatment accessories, and quality assurance software; and information management, treatment planning, image processing, clinical knowledge exchange, patient care management, decision-making support, and practice management software. This segment serves university research and community hospitals, private and governmental institutions, healthcare agencies, physicians' offices, medical oncology practices, radiotherapy centers, and cancer care clinics. The Proton Solutions segment designs, develops, manufactures, sells, and services products and systems for delivering proton therapy for the treatment of cancer. The company has a strategic agreement with McKesson Corp. to supply treatment delivery systems and planning, services, and radiotherapy information system solutions to its U.S. Oncology Network and Vantage Oncology affiliated sites of care; and a strategic partnership with Siemens AG to represent Siemens diagnostic imaging products to radiation oncology clinics in the United States and other select markets. Varian Medical Systems, Inc. was formerly known as Varian Associates, Inc. and changed its name to Varian Medical Systems, Inc. in April 1999. The company was founded in 1948 and is headquartered in Palo Alto, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Sep '12 Sep '13 Sep '14 Jul '15 Oct '15 Jul '16 Sep '17 Sep '18 Sep '19 Jul '20 Oct '20
Equity (BVPS) 13.38
15.81
16.99
17.51
18.02
15.16
16.42
19.20
21.21
growth rate 18.2% 7.5% 3.1% 1.5% -15.9% 8.3% 16.9% 10.5%
Earnings BIT 595.92
612.08
597.00
407.90
429.90
347.70
494.50
498.10
421.60
growth rate 2.7% -2.5% -17.3% 5.4% -19.1% 42.2% 0.7% -8.0%
Avg.PE 16.05
18.76
23.11
19.62
21.99
37.00
76.17
35.59
59.72
59.72
growth rate 16.9% 23.2% -7.9% 12.1% 68.3% 105.9% -53.3% 67.8% 0.0%
ROA 15.88
13.81
11.83
11.83
10.85
7.14
4.66
7.94
6.29
growth rate -13.0% -14.3% 0.0% -4.2% -34.2% -34.7% 70.4% -20.8%
ROE 31.02
27.19
24.24
24.73
23.31
15.43
9.74
17.41
14.01
growth rate -12.4% -10.9% 2.0% -2.9% -33.8% -36.9% 78.8% -19.5%
ROIC 27.36
22.41
18.78
19.11
17.26
12.48
9.24
13.78
11.23
growth rate -18.1% -16.2% 1.8% -5.0% -27.7% -26.0% 49.1% -18.5%
Cur. Ratio 1.76
2.33
2.08
1.83
1.62
1.41
1.63
1.27
1.40
growth rate 32.4% -10.7% -12.0% -5.9% -13.0% 15.6% -22.1% 10.2%
Quick Ratio 1.17
1.62
1.37
1.17
1.13
0.99
1.13
0.87
0.98
growth rate 38.5% -15.4% -14.6% -1.7% -12.4% 14.1% -23.0% 12.6%
Leverage 1.91
2.02
2.07
2.10
2.19
2.13
2.05
2.32
2.15
growth rate 5.8% 2.5% 1.5% 2.1% -2.7% -3.8% 13.2% -7.3%
Balance Sheet Sep '12 Sep '13 Sep '14 Jul '15 Oct '15 Jul '16 Sep '17 Sep '18 Sep '19 Jul '20 Oct '20
Acct.Receivable 807.59
820.50
731.93
780.90
804.60
1,015.60
1,058.90
1,153.50
1,127.10
growth rate 1.6% -10.8% 3.3% 3.0% 26.2% 4.3% 8.9% -1.2%
Acct.Payable 659.28
675.80
187.38
202.90
159.20
162.30
190.30
248.50
194.90
growth rate 2.5% -72.3% 4.1% -21.5% 2.0% 17.3% 30.6% -11.4%
Cur.Assets 2,170.52
2,704.78
2,494.17
2,393.00
2,615.40
2,296.80
2,188.40
2,395.40
2,603.30
growth rate 24.6% -7.8% -2.1% 9.3% -12.2% -4.7% 9.5% 4.3%
Total Assets 2,878.73
3,468.47
3,357.29
3,578.70
3,814.80
3,294.40
3,252.70
4,101.70
4,462.20
growth rate 20.5% -3.2% 3.2% 6.6% -13.6% -1.3% 26.1% 4.3%
Cash 704.57
1,117.86
849.28
845.50
811.40
716.20
504.80
531.40
766.10
growth rate 58.7% -24.0% -0.2% -4.0% -11.7% -29.5% 5.3% 20.1%
Inventory 457.87
535.22
572.26
612.60
442.40
417.70
438.10
551.50
516.30
growth rate 16.9% 6.9% 3.5% -27.8% -5.6% 4.9% 25.9% -3.2%
Cur.Liabilities 1,236.53
1,160.58
1,201.65
1,376.70
1,613.40
1,645.10
1,339.70
1,884.00
1,854.50
growth rate -6.1% 3.5% 7.0% 17.2% 2.0% -18.6% 40.6% -0.8%
Liabilities 1,368.95
1,754.63
1,740.87
1,852.40
2,060.30
1,772.50
1,664.00
2,324.10
2,377.40
growth rate 28.2% -0.8% 3.2% 11.2% -14.0% -6.1% 39.7% 1.1%
LT Debt 6.25
450.00
387.50
337.50
286.90
growth rate 7,100.0% -13.9% -6.7% -15.0%
Equity 1,509.78
1,713.85
1,616.42
1,711.60
1,740.50
1,517.60
1,584.40
1,768.30
2,075.50
growth rate 13.5% -5.7% 2.9% 1.7% -12.8% 4.4% 11.6% 8.3%
Common Shares 113.00
110.00
105.00
100.00
96.00
93.00
93.00
92.00
91.20
growth rate -2.7% -4.6% -2.4% -4.0% -3.1% 0.0% -1.1% -0.9%
Cash Flow Statement Sep '12 Sep '13 Sep '14 Jul '15 Oct '15 Jul '16 Sep '17 Sep '18 Sep '19 Jul '20 Oct '20
Capital Expenditures 61.10
76.28
89.60
91.40
80.40
59.10
47.70
58.00
84.30
growth rate 24.8% 17.5% 1.0% -12.0% -26.5% -19.3% 21.6% 20.6%
Cash Dividends 0.00
growth rate
Cash From OA 492.78
455.19
449.00
469.60
356.30
399.10
454.90
371.80
484.10
growth rate -7.6% -1.4% 2.3% -24.1% 12.0% 14.0% -18.3% 14.1%
FCF per Share 3.39
3.73
3.07
4.19
2.70
3.86
4.61
3.28
2.91
growth rate 10.0% -17.7% 36.5% -19.7% 43.0% 19.4% -28.9% -11.3%
Sale Purchase of Stock -197.11
-290.35
99.70
91.00
60.60
72.10
growth rate 0.0% 100.0% -4.5% -33.4% 19.0%
FCF 432.00
379.00
359.00
378.00
378.20
275.00
340.00
407.00
314.00
400.00
399.80
growth rate -12.3% -5.3% 5.3% 0.1% -27.3% 23.6% 19.7% -22.9% 27.4% -0.1%
Income Statement Sep '12 Sep '13 Sep '14 Jul '15 Oct '15 Jul '16 Sep '17 Sep '18 Sep '19 Jul '20 Oct '20
Sales 2,807.02
2,942.90
3,049.80
2,490.70
2,593.70
2,619.30
2,919.10
3,225.10
3,168.20
growth rate 4.8% 3.6% -9.6% 4.1% 1.0% 11.5% 10.5% -0.9%
Op.Income 427.05
438.25
597.00
407.90
429.90
347.70
494.50
498.10
421.60
growth rate 2.6% 36.2% -17.3% 5.4% -19.1% 42.2% 0.7% -8.0%
IBT 595.92
612.08
574.50
401.30
432.40
303.10
452.10
420.80
358.30
growth rate 2.7% -6.1% -16.4% 7.8% -29.9% 49.2% -6.9% -7.7%
Net Income 427.05
438.25
403.70
411.50
399.30
218.50
149.90
291.90
269.20
growth rate 2.6% -7.9% 1.0% -3.0% -45.3% -31.4% 94.7% -4.0%
EPS 3.76
3.98
3.83
4.09
4.16
2.35
1.62
3.18
2.94
growth rate 5.9% -3.8% 6.8% 0.9% -43.5% -31.1% 96.3% -7.6%
Gross Profit 1,196.34
1,249.69
1,301.70
1,032.10
1,104.70
1,113.90
1,273.60
1,370.30
1,377.20
growth rate 4.5% 4.2% -11.0% 7.0% 0.8% 14.3% 7.6% 0.3%
R&D 185.74
208.21
234.80
195.40
200.40
210.00
233.90
247.60
280.60
growth rate 12.1% 12.8% -8.8% 2.6% 4.8% 11.4% 5.9% 6.5%

Quarterly Statements

Item Name Sep '19 Jan '20 Apr '20 Jul '20 Oct '20
Earnings BIT 135.40
121.80
91.50
88.70
118.20
growth rate -10.0% -24.9% -3.1% 33.3%
Balance Sheet Sep '19 Jan '20 Apr '20 Jul '20 Oct '20
Acct.Receivable 1,153.50
1,128.50
1,014.80
987.40
1,127.10
growth rate -2.2% -10.1% -2.7% 14.2%
Acct.Payable 248.50
215.30
198.40
164.50
194.90
growth rate -13.4% -7.9% -17.1% 18.5%
Cur.Assets 2,395.40
2,647.00
2,500.90
2,631.70
2,603.30
growth rate 10.5% -5.5% 5.2% -1.1%
Total Assets 4,101.70
4,450.70
4,343.90
4,454.40
4,462.20
growth rate 8.5% -2.4% 2.5% 0.2%
Cash 531.40
721.90
667.80
769.20
766.10
growth rate 35.9% -7.5% 15.2% -0.4%
Inventory 551.50
597.40
604.00
600.40
516.30
growth rate 8.3% 1.1% -0.6% -14.0%
Cur.Liabilities 1,884.00
2,046.40
1,949.70
1,991.40
1,854.50
growth rate 8.6% -4.7% 2.1% -6.9%
Liabilities 2,324.10
2,593.40
2,473.20
2,511.30
2,377.40
growth rate 11.6% -4.6% 1.5% -5.3%
LT Debt
growth rate
Equity 1,768.30
1,847.30
1,860.80
1,933.50
2,075.50
growth rate 4.5% 0.7% 3.9% 7.3%
Common Shares 90.80
90.70
90.70
90.90
91.20
growth rate -0.1% 0.0% 0.2% 0.3%
Cash Flow Statement Sep '19 Jan '20 Apr '20 Jul '20 Oct '20
Capital Expenditures 14.30
22.60
14.40
18.00
29.30
growth rate 58.0% -36.3% 25.0% 62.8%
Cash Dividends
growth rate
Cash From OA 117.80
112.60
21.90
83.00
266.60
growth rate -4.4% -80.6% 279.0% 221.2%
Sale Purchase of Stock
growth rate
FCF 103.50
90.00
7.50
65.00
237.30
growth rate -13.0% -91.7% 766.7% 265.1%
Income Statement Sep '19 Jan '20 Apr '20 Jul '20 Oct '20
Sales 878.90
828.90
794.50
694.30
850.50
growth rate -5.7% -4.2% -12.6% 22.5%
Op.Income 135.40
121.80
91.50
88.70
118.20
growth rate -10.0% -24.9% -3.1% 33.3%
IBT 110.40
112.70
52.80
84.80
108.00
growth rate 2.1% -53.2% 60.6% 27.4%
Net Income 70.70
88.20
43.20
61.20
76.60
growth rate 24.8% -51.0% 41.7% 25.2%
EPS
growth rate
Gross Profit 384.60
366.80
337.20
298.50
374.70
growth rate -4.6% -8.1% -11.5% 25.5%
R&D 65.20
67.10
71.00
65.30
77.20
growth rate 2.9% 5.8% -8.0% 18.2%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

D (33.35)

YOY Growth Grade:

E (27.19)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 59.67 59.68 28.57
EPS / Growth 2.2% 2.94 9.9%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 7.3%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 2.2% 6.5% 6.5%
Future PE 4.42 33.73 33.73
Future EPS 3.66 5.51 5.51
Value Price
MOS %
4.00
-97.7%
45.93
-73.8%
45.93
-73.8%
MOS Price 2.00 22.97 22.97
IRT 37.91 24.41 24.41

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.